Last reviewed · How we verify
Cetuximab, irinotecan — Competitive Intelligence Brief
phase 2
Small molecule
Live · refreshed every 30 min
Target snapshot
Cetuximab, irinotecan (Cetuximab, irinotecan) — Asan Medical Center.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Cetuximab, irinotecan TARGET | Cetuximab, irinotecan | Asan Medical Center | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Cetuximab, irinotecan CI watch — RSS
- Cetuximab, irinotecan CI watch — Atom
- Cetuximab, irinotecan CI watch — JSON
- Cetuximab, irinotecan alone — RSS
Cite this brief
Drug Landscape (2026). Cetuximab, irinotecan — Competitive Intelligence Brief. https://druglandscape.com/ci/cetuximab-irinotecan. Accessed 2026-05-18.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab